FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.
You may also be interested in...
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half
Firm reports first-quarter revenues of over $1 billion.